Middle East Pharmaceutical Industries Company vs Viatris Inc.
A head-to-head of Middle East Pharmaceutical Industries Company (4016) and Viatris Inc. (VTRS) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | 4016 | VTRS |
|---|---|---|
| Market Cap | 2.06B SAR | $20.14B |
| P/E (TTM) | 12.46 | — |
| Forward P/E | 11.57 | 6.17 |
| P/S | 4.19 | 1.32 |
| P/B | 5.07 | 1.48 |
| EV/EBITDA | 9.59 | 7.62 |
| Dividend Yield | 2.39% | 2.56% |
| Profit Margin | 21.19% | -2.04% |
| Gross Margin | 62.29% | 35.06% |
| Operating Margin | 23.74% | 1.77% |
| Revenue Growth (YoY) | +33.65% | +8.07% |
| FCF Yield | 1.62% | 8.62% |
| Debt / Equity | 19.87 | 97.84 |
| Current Ratio | 2.85 | 1.60 |
Which is better: Middle East Pharmaceutical Industries Company or Viatris Inc.?
- ✓Larger by market cap: Viatris Inc.
- ✓Higher dividend yield: Viatris Inc.
- ✓More profitable (net margin): Middle East Pharmaceutical Industries Company
- ✓Faster revenue growth: Middle East Pharmaceutical Industries Company
- ✓Higher free-cash-flow yield: Viatris Inc.
Very close — each leads on 6 metrics.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Middle East Pharmaceutical Industries Company with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.